Explanatory Note

This bill limits the sale of crystal meth precursors in British Columbia by providing that

• crystal meth precursors may only be sold from licensed pharmacies in British Columbia,
• single entity crystal meth precursors must be retained within the Professional Service Area of licensed pharmacies and may only be sold by a pharmacist after discussing with the purchaser the condition to be treated, and
• a pharmacist may not sell by retail single entity pseudoephedrine products in a quantity that results in the purchaser receiving more than 3,600 mg pseudoephedrine,
• Multi-entity crystal meth precursors must be sold by a pharmacist from the self-selection Professional Products Area of a pharmacy.

BILL M 207 – 2006
CRYSTAL METH PREVENTION ACT, 2006

Contents

HER MAJESTY, by and with the advice and consent of the Legislative Assembly of the Province of British Columbia, enacts as follows:

Definitions

1 In this Act,

"crystal meth" means crystal methamphetamine;

"multi-entity crystal meth precursors" includes multi-entity

(a) pseudoephedrine products, and

(b) ephedrine products, in preparations containing no more than 8 mg of ephedrine per unit dose, with a label recommending no more than 8 mg per dose or 32 mg per day, labeled or implied for use not exceeding 7 days, and indicated for nasal congestions;

"pharmacist" has the same meaning as in the Pharmacists, Pharmacy Operations and Drug Scheduling Act;

"pharmacy" means the area of a premises licensed under the Pharmacists, Pharmacy Operations and Drug Scheduling Act where drugs or devices may be stored, dispensed or sold to the public;

"prescription" has the same meaning as in the Pharmacists, Pharmacy Operations and Drug Scheduling Act;

"Professional Products Area" has the same meaning as in Bylaw 5 (25) of the bylaws to the Pharmacists, Pharmacy Operations and Drug Scheduling Act;

"Professional Service Area" has the same meaning as in Bylaw 5 (25) of the bylaws to the Pharmacists, Pharmacy Operations and Drug Scheduling Act;

"single entity crystal meth precursors" includes single entity

(a) pseudoephedrine products, and

(b) ephedrine products, in preparations containing no more than 8 mg of ephedrine per unit dose, with a label recommending no more than 8 mg per dose or 32 mg per day, labeled or implied for use not exceeding 7 days, and indicated for nasal congestions.

Sale of crystal meth precursors limited to pharmacies

2 Single entity and multi-entity crystal meth precursors may only be sold from pharmacies.

Limits on sale of single entity crystal meth precursors

3 (1) Single entity crystal meth precursors

(a) may be sold by a pharmacist on a nonprescription basis only after discussing with the purchaser the condition or symptoms to be treated, and

(b) must be retained within the Professional Service Area of the pharmacy where there is no public access and no opportunity for patient self-selection.

(2) A pharmacist must not sell by retail single entity pseudoephedrine products in a quantity that results in the purchaser receiving, at the time of purchase, more than 3,600 mg of pseudoephedrine.

Limits on sale of multi-entity crystal meth precursors

4 Multi-entity crystal meth precursors may be sold by a pharmacist to any person from the self-selection Professional Products Area of a pharmacy.

 
Explanatory Note

This bill limits the sale of crystal meth precursors in British Columbia by providing that

• crystal meth precursors may only be sold from licensed pharmacies in British Columbia,
• single entity crystal meth precursors must be retained within the Professional Service Area of licensed pharmacies and may only be sold by a pharmacist after discussing with the purchaser the condition to be treated, and
• a pharmacist may not sell by retail single entity pseudoephedrine products in a quantity that results in the purchaser receiving more than 3,600 mg pseudoephedrine,
• Multi-entity crystal meth precursors must be sold by a pharmacist from the self-selection Professional Products Area of a pharmacy.